Response by organ system
| Dose group3-150 . | Skin . | Liver . | Upper GI . | Lower GI . | ||||
|---|---|---|---|---|---|---|---|---|
| 0.01 . | 0.1-0.3 . | 0.01 . | 0.1-0.3 . | 0.01 . | 0.1-0.3 . | 0.01 . | 0.1-0.3 . | |
| Patients evaluated | 5 | 27 | 4 | 21 | 5 | 26 | 5 | 21 |
| CR | ||||||||
| n | 1 | 14 | 0 | 4 | 1 | 16 | 2 | 13 |
| % | 20 | 52 | 0 | 19 | 20 | 61 | 40 | 62 |
| Improved | ||||||||
| n | 2 | 8 | 0 | 2 | 0 | 1 | 0 | 4 |
| % | 40 | 30 | 0 | 9 | 0 | 4 | 0 | 19 |
| Stable | ||||||||
| n | 1 | 3 | 2 | 6 | 4 | 6 | 1 | 3 |
| % | 20 | 11 | 50 | 29 | 80 | 23 | 20 | 14 |
| Progressed | ||||||||
| n | 1 | 2 | 2 | 9 | 0 | 3 | 2 | 1 |
| % | 20 | 7 | 50 | 43 | 0 | 12 | 40 | 5 |
| Dose group3-150 . | Skin . | Liver . | Upper GI . | Lower GI . | ||||
|---|---|---|---|---|---|---|---|---|
| 0.01 . | 0.1-0.3 . | 0.01 . | 0.1-0.3 . | 0.01 . | 0.1-0.3 . | 0.01 . | 0.1-0.3 . | |
| Patients evaluated | 5 | 27 | 4 | 21 | 5 | 26 | 5 | 21 |
| CR | ||||||||
| n | 1 | 14 | 0 | 4 | 1 | 16 | 2 | 13 |
| % | 20 | 52 | 0 | 19 | 20 | 61 | 40 | 62 |
| Improved | ||||||||
| n | 2 | 8 | 0 | 2 | 0 | 1 | 0 | 4 |
| % | 40 | 30 | 0 | 9 | 0 | 4 | 0 | 19 |
| Stable | ||||||||
| n | 1 | 3 | 2 | 6 | 4 | 6 | 1 | 3 |
| % | 20 | 11 | 50 | 29 | 80 | 23 | 20 | 14 |
| Progressed | ||||||||
| n | 1 | 2 | 2 | 9 | 0 | 3 | 2 | 1 |
| % | 20 | 7 | 50 | 43 | 0 | 12 | 40 | 5 |
ABX-CBL dose group, mg/kg.
n indicates number of patients.